Speaking exclusively to BioSpectrum on the occasion, Mr. Sohang Chatterjee, director & CEO of the company expressed, "Biotechnology has now become the prime instrument in conquering that final frontier of medicine-personalised therapy. Theramyt seeks to be a leader in biological drug development, to develop advanced biologics through cutting edge technology platforms that would deliver affordable and best-in-quality drug products."

Ms Kavitha Iyer Rodrigues, Theramyt's cofounder and director opined, "With this GLP-compliant facility, we are committed to delivering high quality, premium customer support, and outstanding value, through innovation and continuous improvement. Our aim is to occupy a leadership position in global biotech industry with the differentiated biologics developed in our facility in Bangalore."

Mr Chatterjee further added that, "In terms of operations, we have learnt a lot about building a company from our past experiences. For us exciting times are ahead. We would need the government's support, both for our R&D and product development foray. A transparent regulatory pathway, a great ecosystem of academia, investors and good science would drive Theramyt to newer horizons of unlocking value in partnerships with MNC's."

According to Ms Iyer Rodrigues, the company has raised about Rs 27.5 crore investments last year from a plethora of venture capitalists including Accel Partners, Aarin Capital, IDG Ventures and Karnataka government's KITVEN (Karnataka Information Technology Venture Capital Fund).

The company firstly intends to focus in the area of anti-cancer followed by rheumatoid arthritis, metabolic diseases and cardio-vascular diseases (CVD).

The company's name was coined by its scientific advisory board, which is a portmanteau of the words, 'therapeutic' and 'might'.

The company was officially registered in July 2013.